All In Biotech

Drug Trial Radar · NCT06712641

Aminoglycosides in Early Sepsis

Aminoglycosides in Early Sepsis (AGES): A Randomized Pragmatic Clinical Trial Comparing Gentamicin and Narrow Spectrum Betalactams to Broad Spectrum Betalactams as Empirical Treatment in Patients With Suspected Sepsis

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,900 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,900

Planned (sponsor's estimate)

Start

Apr 23, 2026

Primary completion

Jun 2028

Study completion May 2033

Sponsor

Lead sponsor
University Hospital, AkershusAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ullevaal University Hospital
First posted
Dec 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Norwegian guidelines for empirical antibiotic therapy in suspected community acquired sepsis recommend the combination of narrow spectrum betalactam and aminoglycoside as the first choice, but broad spectrum betalactams are considered equally appropriate, effective, and safe. However, fear of renal complications due to gentamicin and concern for lacking evidence for efficiency commonly leads to the use of broad spectrum betalactam therapy, a larger driver of antibiotic resistance. In patients with suspected community acquired sepsis, the investigators hypothesize that empirical combination therapy with narrow spectrum betalactams and aminoglycosides is safe and non-inferior to empirical therapy with broad spectrum betalactams. More specifically, the investigators hypothesize that the proportion of patients with acute kidney injury or death will be similar between these two treatment groups. Furthermore, the investigators hypothesize that the aminoglycoside-based regimen has lesser impact on the gut microbiome. Antimicrobial resistance is one of the most urgent health threats of our time, and Norwegian hospitals were required but failed to reduce the use of broad-spectrum antibiotics with 30% by the end of 2020. In this context, novel initiatives aiming at reducing use of antibiotics are direly needed.

Conditions

  • Sepsis

Interventions

  • Gentamicin + narrow spectrum betalactamDrug

    Empirical therapy for suspected community-acquired sepsis with gentamicin + narrow spectrum betalactam (either one of penicillin, ampicillin, or cloxacillin)

  • CefotaximeDrug

    Empirical therapy for suspected community-acquired sepsis with cefotaxime

  • Piperacillin-tazobactamDrug

    Empirical therapy for suspected community-acquired sepsis with piperacillin-tazobactam

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 30-day mortalityTime frame: Up to 30 days after randomization
  2. 30-day acute kidney injuryTime frame: Up to 30 days after randomization

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Ålesund Hospital, Helse Møre og Romsdal HF

    Ålesund, Norway · Not yet recruiting

  • Bodø Hospital Nordlandssykehuset HF

    Bodø, Norway · Not yet recruiting

  • Drammen Hospital, Vestre Viken HF

    Drammen, Norway · Not yet recruiting

  • Bærum Hospital, Vestre Viken Hospital Trust

    Gjettum, Norway · Not yet recruiting

  • Østfold Hospital Kalnes HF

    Grålum, Norway · Not yet recruiting

  • Nordmøre and Romsdal Hospital, Helse Møre og Romsdal HF

    Hjelset, Norway · Not yet recruiting

  • Ringerike Hospital, Vestre Viken Hospital Trust

    Hønefoss, Norway · Not yet recruiting

  • Akershus University Hospital

    Lørenskog, Norway · Recruiting

  • Oslo University Hospital Ullevål

    Oslo, Norway · Recruiting

  • Sykehuset Telemark Skien

    Skien, Norway · Not yet recruiting

  • Vestfold Hospital HF

    Tønsberg, Norway · Not yet recruiting

  • University Hospital of North Norway

    Tromsø, Norway · Not yet recruiting

  • Haukeland University Hospital

    Bergen, Bergen, Norway · Recruiting

  • Lovisenberg Diakonal Hospital

    Oslo, Oslo, Norway · Recruiting

  • St. Olav's Hospital

    Trondheim, Trondheim, Norway · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.